Delayed Graft Function  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01919346: Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation

Terminated
2
21
US
Eculizumab, Soliris, Normal Saline
Heeger, Peter, M.D., Alexion Pharmaceuticals, Icahn School of Medicine at Mount Sinai
Delayed Graft Function, Kidney Transplantation, Complement Activity
12/17
12/17

Download Options